ArticleWorld journal of psychiatry2019
Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis.
Article in World journal of psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 20 citations in OpenAlex.
- Review
- Article
- Improving recognition and management of inpatient delirium in Parkinson's disease: evidence review and implications for clinical care.Frontiers in aging neuroscience · 2025Review
- Clinical characteristics and treatment of psychosis in Parkinson's disease: A narrative review.Journal of the Chinese Medical Association : JCMA · 2024Review
- Clozapine for Management of Neuropsychiatric Symptoms in Dementia with Lewy Bodies: Case Report and Literature Review.The Canadian journal of hospital pharmacy · 2023Article
- Emerging role of psychosis in Parkinson's disease: From clinical relevance to molecular mechanisms.World journal of psychiatry · 2022Review
- Identification of Potential Parkinson's Disease Drugs Based on Multi-Source Data Fusion and Convolutional Neural Network.Molecules (Basel, Switzerland) · 2022Article
- Metabotropic glutamate receptors and nitric oxide in dopaminergic neurotoxicity.World journal of psychiatry · 2021Review
- Time to re-engage psychiatric drug discovery by strengthening confidence in preclinical psychopharmacology.Psychopharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this editorial is to evaluate the evidence for using pimavanserin for the treatment of Parkinson's disease psychosis (PDP) from randomized controlled trials (RCTs). We only identified two published trials that evaluated the use of pimavanserin among individuals with PDP. Both studies found that pimavanserin improved psychotic symptoms among individuals with PDP when compared to placebo. Pimavanserin was fairly well tolerated in both studies and did not appear to cause significant sedation or worsen motor symptoms among individuals with PDP. However, given the limited data, additional confirmatory studies are required before pimavanserin can be considered as a first line agent for the treatment of psychotic symptoms among individuals with PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.